Leadership
Dedication, Expertise, Passion
Founder & Chief Executive Officer
Moncef Jendoubi, Ph.D.
Dr. Jendoubi holds an M.S. in Genetics, an M.S. in Biochemistry, a Ph.D. in Molecular Biology, a “Doctorat D’Etat Es Sciences” in Immunology, and a diploma in Bacteriology from the University of Paris. He trained at the Pasteur Institute, where he held the position of Associate Professor. In 1987, he joined the National Institutes of Health (NIH) as Visiting Professor and became Chief of the Genetics and Molecular Immunology Section in 1990. At the NIH, his research focused on cell-cell communication pathways. He has authored dozens of publications and holds several patents.
Director of Operations & Regulatory Compliance
Christine Chavany, PhD, RAC
Dr Chavany has led Milagen’s R&D effort in cancer biomarker discovery and development since the inception of the company in 1997. She has been a key figure in the development of all company’s technologies, from antibody screening to biomarker discovery, and from monoclonal antibody production to immunoassay development. Dr. Chavany has also been a Principal Investigator in numerous NIH-SBIR-funded projects. Dr. Chavany oversees the GMP manufacturing of Milagen diagnostic product pipeline and provides guidance in regulatory affairs and compliance, closely working with the Regulatory Team. Dr. Chavany received her Ph.D. in Pharmaceutical Sciences from the University of Paris XI-Orsay in 1991 and trained at the National Cancer Institute of the NIH from 1991 to 1997 focusing on the anti-cancer activity of antisense oligonucleotides and drugs, and characterization of transgenic mice as a model for neurodegenerative diseases. Prior to joining Milagen, she held Scientist positions in the biotech sector. Dr. Chavany is a member of the American Association for Cancer Research (AACR) and is Regulatory Affair Certified by the Regulatory Affair Professional Society since 2001.
Clinical Laboratory Director
Dr. Merl Arthur Charles M.D. Ph.D
Dr. M. Arthur Charles is a Professor at the University of California, San Francisco, and is Board Certified in Internal Medicine and Endocrinology, Diabetes & Metabolism with more than 55 years of basic research and clinical experience. Dr. Charles is a physician/scientist who completed medical school at the University of California, Irvine (UCI), an Internal Medicine Internship and Residency at Walter Reed Army Medical Center and a PhD in Endocrinology at the University of California, San Francisco. His research has led to over 120 peer-reviewed publications, with many involving innovative laboratory biochemical methods. Dr. Charles developed the Diabetes Research Program at UCI, where he served as professor for 21 years. The Diabetes Program included basic science research, clinical research and tertiary clinical care for diabetic patients. He moved the clinical research unit into a private company, University Clinical Investigators, which is still active 25 years later. The Program was internationally recognized for research type 1 diabetes immunology and for its development of implantable insulin delivery devices, first in dogs and then in humans.
Director of Immunoassay Development
Jeffrey Dea
Jeff is a highly skilled scientist who has dedicated 16 years of his career to Milagen. He has been extensively involved in various aspects of Milagen's immunoassay development and played a key role in the company's monoclonal antibody production, validation and commercialization. His current responsibilities include CLIA Assay development, Reagent Production and Training of new lab technicians in coordination with the Regulatory Team. A deep believer in continuous learning, Jeff graduated from the University of California, Berkeley and continues to acquire new skillsets, most recently machine learning and data science.